Gemcitabine in the Treatment of Refractory Hodgkin’s Disease: Results of a Multicenter Phase II Study

Santoro, Armando; Bredenfeld, Henning; Devizzi, Liliana; Tesch, Hans; Bonfante, V.; Viviani, Simonetta; Fiedler, F.; Parra, Héctor Soto; Benoehr, C.; Pacini, M.; Bonadonna, Gianni; Diehl, Volker

doi:10.1200/jco.2000.18.13.2615

Cited by 207 publications

(132 citation statements)

References 35 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Preclinical studies of gemcitabine and cisplatin have demonstrated synergy both in vitro and in vivo (Peters et al, 1995). Phase I studies evaluating this combination in relapsed and refractory HL and NHL have also reported higher RRs (Aviles et al, 2004;Emmanouilides et al, 2004) compared to either agent given as monotherapy (Fossa et al, 1999;Santoro et al, 2000;Savage et al, 2000;Zinzani et al, 2000). The mechanisms underlying this synergy may be due to increased incorporation of gemcitabine into DNA and RNA, and increased cisplatin -DNA adduct formation by inhibition of exonuclease and DNA repair (van Moorsel et al, 1999).…”

mentioning

confidence: 99%

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

Waters

Cunningham

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

There is currently no standard salvage chemotherapy regimen in relapsed and refractory lymphoma. Gemcitabine is a novel nucleoside analogue, which acts synergistically with cisplatin both in vitro and in clinical studies. We evaluated the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) in 41 heavily pretreated patients with relapsed and refractory Hodgkin's and non-Hodgkin's lymphoma. The best-achieved response rate (RR) was 79% (95% CI 64 -91), with a complete RR of 21%. In patients with chemo-resistant disease, the RR was 63%. Myelosuppression was the main toxicity, the incidence of Grade 3 or 4 anaemia, neutropenia and thrombocytopenia was 17.1, 61.0 and 53.7% respectively. Only one patient had neutropenic sepsis and none of the patients suffered from haemorrhage. Grade 3 or 4 nonhaematological toxicity was minimal and stem cell mobilisation was not inhibited. GEM-P is an effective salvage regimen and its use prior to autologous stem cell transplant warrants further investigation.

show abstract

mentioning

confidence: 99%

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

Waters

Cunningham

et al. 2005

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In the field of hematology, gemcitabine has been demonstrated to be active in heavily pretreated patients with Hodgkin disease, 15,16 as well as those with aggressive and indolent non-Hodgkin lymphoma. 17,18 The objective of the current study was to determine the role of gemcitabine in previously treated (only local radiotherapy or PUVA therapy) or untreated patients with advanced MF and peripheral T-cell lymphoma, unspecified, with skin involvement (PTCLU).…”

mentioning

confidence: 99%

Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma

Marchi

Alinari

Tani

et al. 2005

Cancer

142

View full text Add to dashboard Cite

BACKGROUNDBased on the activity of gemcitabine in heavily pretreated patients with cutaneous T‐cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL.METHODSBetween June 2002 and February 2004, 32 untreated patients with mycosis fungoides (MF) (n = 26 patients); peripheral T‐cell lymphoma, unspecified (PTCLU) with exclusive skin involvement (n = 5 patients); and Sezary syndrome (SS) (n = 1 patient) were enrolled in a 7‐institution, Phase II trial and treated with gemcitabine. This drug was given on Days 1, 8, and 15 of a 28‐day schedule at a dose of 1200 mg/m2 intravenously over 30 minutes for a total of 6 cycles.RESULTSOf the 32 patients studied, 7 (22%) achieved a complete response (CR) and 17 (53%) achieved a partial response (PR), whereas the remaining 8 patients showed no benefit from the treatment. Five of the CRs were confirmed histologically. The CR and PR rates were found to be the same for patients with MF and PTCLU, respectively. The median duration of CR was 10 months (range, 4–22 mos). Treatment appeared to be well tolerated; hematologic toxicity was mild and no nausea/emesis or organ toxicity was noted.CONCLUSIONSThe results of the current Phase II study demonstrate the activity of gemcitabine as a single agent in untreated CTCL patients. Further studies using gemcitabine in combination, either contemporary or sequentially, with other drugs in patients with advanced stage, untreated CTCL are needed. Cancer 2005. © 2005 American Cancer Society.

show abstract

“…3 Experience in myeloid malignancies has been limited. Grunewald et al reported a Phase I study administering gemcitabine at a dose of 10 mg/m 2 per minute to maximize the accumulation of the drug in leukemia cells.…”

Section: Gemcitabinementioning

confidence: 99%

New agents in acute myeloid leukemia and other myeloid disorders

Ravandi

Kantarjian

Giles

et al. 2004

Cancer

View full text Add to dashboard Cite

Gemcitabine in the Treatment of Refractory Hodgkin’s Disease: Results of a Multicenter Phase II Study

Abstract: Gemcitabine was shown to be active in heavily pretreated patients with Hodgkin's disease, producing a response rate of 39%. Additionally, drug-related toxicities were mild, which thus suggests the possible inclusion of gemcitabine in an earlier phase of treatment.

Cited by 207 publications

References 35 publications

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma

New agents in acute myeloid leukemia and other myeloid disorders

Contact Info

Product

Resources

About